Natalie Beckett, DO
Internal Medicine · Columbus, OHNPI 1710373493
Payments from drug & device makers
Across 156 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$437
- Lilly USA, LLC$289
- AstraZeneca$144
- GSK$142
- Viiv Healthcare Company$141
- Astellas Pharma US Inc$136
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $437 |
| Lilly USA, LLC | 16 | $289 |
| AstraZeneca | 10 | $144 |
| GSK | 8 | $142 |
| Viiv Healthcare Company | 7 | $141 |
| Astellas Pharma US Inc | 8 | $136 |
| Amgen(2 entities) | 7 | $122 |
| Novo Nordisk | 7 | $110 |
| Bayer | 5 | $108 |
| Merck | 6 | $94 |
| Alphatec Spine, Inc | 2 | $72 |
| Boehringer Ingelheim | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Exact Sciences | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Boston Scientific | 2 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Pfizer | 2 | $37 |
| Dexcom, Inc. | 2 | $33 |
| Averitas Pharma Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Edwards Lifesciences | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Bausch Health US, LLC | 2 | $25 |
| Abbott | 1 | $23 |
| Optinose US, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| BD | 1 | $18 |
| Novartis | 1 | $18 |
| Kaleo, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,634 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 62 | $89,442 |
| EliquisApixaban | 42 | $46,982 |
| OzempicSemaglutide | 39 | $39,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $25,575 |
| JardianceEmpagliflozin | 23 | $24,128 |
| XareltoRivaroxaban | 14 | $20,913 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,808 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,424 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $4,116 |
| SynthroidLevothyroxine Sodium | 42 | $2,711 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,388 |
| Levothyroxine Sodium | 247 | $2,347 |
| Bupropion XlBupropion Hcl | 52 | $2,299 |
| RexultiBrexpiprazole | 13 | $2,051 |
| Atorvastatin Calcium | 195 | $1,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $289 | $89,44262 claims |
| PfizerEliquis | $37 | $46,98242 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $142 | $39,49966 claims |
| Novo NordiskOzempic | $110 | $39,17539 claims |
| Boehringer IngelheimJardiance | $65 | $24,12823 claims |
| Johnson & JohnsonXarelto | $29 | $20,91314 claims |
| MerckJanumet | $94 | $5,42411 claims |
| AbbVieSynthroid | $437 | $2,71142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $39 | $2,347247 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $2,05113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Columbus
- Raghu KolluriColumbus$933K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.